DeepScribe vs Freed (2026)
This pairing nearly sorts itself, because each vendor states plainly what it is not for. DeepScribe is explicit that its fit is complex longitudinal specialty care rather than short low acuity visits: oncology as its center of gravity, tuned models for six further specialties, bidirectional integration writing discrete EHR fields, and the highest independent rating in the lane at 98.8 on the KLAS Emerging Company Spotlight, sold through enterprise sales with no trial. Freed states its strength is primary care and that specialty depth beyond it is a known weakness: published pricing from $39 a month, a Business Associate Agreement by default, same day setup, and a browser extension push with no native write back. If your failure mode is specialty documentation, oncology above all, and you can run a procurement process, start with DeepScribe. If your failure mode is a primary care caseload and needing working notes this week, start with Freed. Match the tool to the caseload; neither pretends to cover the other's.
- Specialty depth is the requirement: oncology as its center of gravity with a reported 40 percent of US cancer care visits, tuned models for six further specialties, and an explicit fit for complex longitudinal specialty care, exactly the caseload Freed states is its weakness.
- The evidence is one sided: a 98.8 KLAS Emerging Company Spotlight score with A plus marks across all six categories and an August 2025 Journal of Clinical Pathways study in oncology, where Freed's clinical evidence is unassessed on this index.
- Structured data must land in the chart: bidirectional integration writes discrete EHR fields with HCC, CPT, and ICD-10 suggestions built into the note, in more than 110 languages, against Freed's browser extension push with no native write back.
- You can see the whole cost before talking to anyone: $39 Starter, $79 Core unlimited, $119 Premier with EHR Push and coding, and a seven day trial with no credit card, where DeepScribe runs enterprise sales with no self serve signup and no trial.
- Compliance comes standard at the entry tier: a HIPAA Business Associate Agreement by default on all tiers, SOC 2 Type II, automatic deletion of recordings, and an opt out from model training.
- Zero deployment is the feature: sign up and generate notes the same day; community health center Camarena Health deployed 55 clinicians across 24 sites without formal implementation, on a base of more than 25,000 clinicians and 32 million transcribed visits.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DeepScribe and Freed are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DeepScribe | Freed |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2017 | 2022 |
| Headquarters | San Francisco, California | San Francisco, California |
| Website | deepscribe.ai | getfreed.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards DeepScribe its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and EHR and Interoperability Depth. Set against Freed, DeepScribe grades higher on Clinical and Operational Evidence, EHR and Interoperability Depth and Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Freed its top capability grade on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Set against DeepScribe, Freed grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose DeepScribe or Freed?
On the axes where the AI Health Index separates them, DeepScribe grades higher on Clinical and Operational Evidence, EHR and Interoperability Depth and Setting and Specialty Coverage, and Freed grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Freed leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do DeepScribe and Freed differ most?
The widest separation the AI Health Index records between DeepScribe and Freed is on Clinical and Operational Evidence, where DeepScribe grades A and Freed grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do DeepScribe and Freed grade the same?
The AI Health Index grades DeepScribe and Freed the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Visit volumes and market share figures for both vendors are vendor published, including DeepScribe's oncology share and Freed's 32 million transcribed visits. Both vendors are unusually candid about their own scope, and this comparison leans on that candour: DeepScribe states its fit is complex longitudinal specialty care rather than short low acuity visits, and Freed's specialty depth outside primary care is a stated weakness with procedure heavy documentation needing more editing.
DeepScribe's KLAS scores are buyer survey based, with the Emerging Company Spotlight a different KLAS instrument from the Best in KLAS category awards held elsewhere in this lane; Freed's clinical evidence is unassessed on this index. Freed's pricing is fully published; DeepScribe publishes none, with third party estimates of $350 to $500 per provider per month and some reports near $750 recorded as unconfirmed estimates.